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ABSTRACT 
Objectives: The study investigated initiation of psychotropic medication in relation to unemployment 
in the months before, during and after job loss to detect the period of greatest risk.  
Methods: The Norwegian working population in 2004 (N=2 348 552) was observed from 2005 to 
2010 through administrative registries linked to the Norwegian Prescription Database. A case-
crossover design was used to analyse within-person relative risk of incident purchases of prescribed 
psychotropic drugs in relation to timing of unemployment. Control periods were defined 12, 24 and 
36 months before the drug purchase. Supplementary analyses were performed on medication for 
cardiovascular disease, diabetes, obesity, thyroid disorder, pain and musculoskeletal conditions. 
Results: Purchases of all psychotropic drugs increased 1-3 months before job loss. Antidepressants 
had the highest estimate in the month before job loss (odds ratio (OR) 2.68, 95% confidence intervals 
(CI) 2.39 to 3.01), followed by hypnotics/sedatives (OR 2.21, 95% CI 1.97 to 2.48), anxiolytics (OR 
2.18, 95% CI 1.91 to 2.48) and antipsychotics (OR 2.09, 95% CI 1.76 to 2.48). Rises were greatest in 
males. Risk of starting psychotropic medication remained raised during a spell of unemployment, but 
returned to close to baseline levels following re-employment. Drugs used to treat somatic and pain 
conditions showed similar trends but with weaker associations.  
 
Conclusions: Concerns about impending unemployment may influence mental health several months 
prior to job loss, especially around the time of notification.  The clinical implications of this might be a 
strengthening of preventive health initiatives early in the unemployment process. 
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INTRODUCTION 
The association between unemployment, mental illness and suicide has been well documented, both 
in earlier times of economic hardship1 and in the wake of the Great Recession.2-4 Further, job loss has 
been related to increased risk of cardiovascular disease, sleeping problems5 and overall mortality.6 
However, as poor health might lead to unemployment7-11 and unemployment might affect health,12-15 
revealing causal health effects of unemployment is an ongoing challenge in this field.16, 17  
People who lose their jobs are usually notified weeks or months before layoff, so the onset of 
possible health effects may start before the date of actual unemployment. It might be relevant to 
distinguish between the acute effects (shock) related to the job loss; stress caused by job insecurity18 
and an anticipation of lowered income, and the effect of actually being unemployed, with its 
economic and social consequences.  Despite this, workers’ health in the days and months before 
unemployment is understudied, probably because lack of detailed data makes it difficult to design 
informative studies. In order to prevent adverse health consequences of unemployment and come 
up with targeted interventions, it is clinically and politically relevant to know at what time in relation 
to job loss people’s mental health is most likely to be affected.  
In this study we investigated how mental health is affected before, during and after an 
unemployment spell by using first-time purchases of prescribed psychotropic medication as a 
measure of increased mental distress. While previous studies in this field are mainly based on self-
reported and/or aggregated data, we had access to individual data on more than two million 
Norwegian employees, including exact dates of purchased medication, unemployment, vocational 
rehabilitation benefits, pensions, emigration and death.  
To account for possible confounding factors associated with both unemployment and mental 
health, study participants were used as their own controls in a case-crossover design.19 We 
investigated how the timing of treatment initiation with prescribed psychotropic drugs in the 
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Norwegian working population varied with unemployment spells over a six year period (2005 to 
2010).  
We hypothesised that mental distress related to an upcoming and ongoing unemployment 
spell would increase the likelihood of initiating treatment with psychotropic drugs before and during 
unemployment, and then decrease when the unemployment spell ended. Furthermore, we 
hypothesised that the increase in the likelihood of initiating drug treatment would be more 
pronounced for psychotropic drugs compared with drugs used for somatic conditions and pain. To 
the best of our knowledge the present study is the first to analyse trajectories of several types of 
psychotropic and somatic drug purchases in relation to unemployment in a whole working 
population with detailed longitudinal data. 
METHODS 
Data provision  
The target population comprised all inhabitants aged 18-67, employed and resident in Norway in 
2004 (N = 2,348,552). Statistics Norway provided individual level registry data on exact dates of 
unemployment and social security benefits (participation in vocational rehabilitation programs, 
disability pension and old age retirement), as well as sex, age, education, emigration and death from 
1992 to 2011 (retirement only until 31.12.2010). The Norwegian Prescription Database (NorPD) was 
established in 2004 and provided individual level data (dates) of all purchased psychotropic drugs 
from Norwegian pharmacies from 2004 and throughout the observation period (2005-2010). The 
drugs were identified by the World Health Organization’s Anatomical Therapeutic Chemical 
classification system (ATC) .  The registries were linked using the personal identification number 
unique to all Norwegian inhabitants.   
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Design and study population  
The association between timing of unemployment and incident use of psychotropic medications was 
analysed using a case-crossover design. In contrast to a conventional case-control design, each 
individual serves as his/her own control in a case-crossover design.20 Hence, all time-invariant or 
slow-varying confounding (e.g. by sex; past psychiatric illness; educational level) is eliminated.19, 21  
However, the case-crossover design still might be susceptible to time varying confounding. 19 The 
design assumes constant risk of exposure; the person-time in the case period is assumed to be 
exchangeable with the same individual’s person-time during control periods.19  
From the target population of 2,348,552 employees, we selected case-crossover samples for 
each group of psychotropic drugs studied; antidepressants (n=34,111), anxiolytics (n=32,570), 
hypnotics/sedatives (n=26,838) and antipsychotics (n=12,495). Each sample consisted of employees 
both exposed to at least one unemployment spell and having a prescribed psychotropic drug 
(outcome) dispensed during the observation period (1 Jan 2005 to 31 Dec 2010). In order to capture 
incident medication, we excluded those who purchased a psychotropic drug in 2004 (N = 307,622).  
16 exposure states of unemployment were defined according to timing of the unemployment 
spell(s): 1-6 months before, 1, 2, 3, “4 or more” months during and 1-6 months after the end of an 
unemployment spell. Further, each individual’s unemployment state was recorded on the date of the 
first drug purchase, henceforth called the case period. Control periods were chosen 12, 24 and 36 
months before the incident drug purchase took place, and each individual’s unemployment state in 
these control periods was recorded (see supplementary file, S-Figure 1). Regarding unemployment, 
we only included individuals who had: 
 
1) At least one episode of unemployment lasting for >90 consecutive days during the 
observation period. Cut off at 90 days was chosen in order to avoid the inclusion of students 
searching for work in holidays and those who were registered as unemployed but secured a 
new job within a short time 
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2) A first episode of unemployment ending no earlier than 180 days before 1 Jan 2005, or an 
unemployment spell starting within the 180 days after 31 Dec 2010 – enabling everyone to 
be situated in any of the 16 time-states in the unemployment process.  
See sample selection flow-chart in Figure 1. 
(Figure 1 here) 
Outcome ascertainment  
The outcome was having a first-time registered purchase of a psychotropic drug during the 
observation period (2005 to 2010). Separate analyses on each of the four psychotropic drug (ATC) 
groups were performed: N06A Antidepressants; N05C Hypnotics and sedatives; N05B Anxiolytics and 
N05A Antipsychotics. A list specifying the drugs and defined daily dose (DDD)/1000 inhabitants/day 
in each group is given in the supplementary file (S-Table 1). Right censoring was done at date of 
death, emigration, retirement (early/old age) or long-term work disability (vocational rehabilitation 
program participation or any type of disability pension), whichever occurred first. 
Exposure to unemployment  
The date of unemployment was defined when an employee was registered completely out of 
income-producing work and signed up as 100% actively job seeking for >90 days, or full-time 
participating in re-employment programs. The observation period was split in 30-days-intervals with 
a maximum of 73 periods (also referred to as months). For each of these periods, we generated 
dichotomous variables indicating unemployment state and first-time drug purchase based on exact 
dates. The dichotomous unemployment variables identified episodes of ongoing unemployment as 
well as the 6-month period leading up to and following each unemployment spell.  
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Main analysis 
We compared the odds of being close to an unemployment spell in the case period (initiation of 
psychotropic drug treatment)  with the odds of being in that same unemployment state 12, 24 and 
36 months before the drug purchase took place (control periods). This takes into account seasonal 
variations in exposure trends, as the same months in each year are used as control periods. An 
indirect measure of relative risk was estimated with the odds ratio (OR) and 95% confidence intervals 
(CI), using a conditional logistic regression (fixed effect) estimator when comparing the odds of 
exposure within each individual’s case and control periods. Statistical software: Stata/MP 13. 
Subgroup analyses 
Subgroup (stratified) analyses were performed according to sex, age and educational level to 
investigate whether associations differed in these groups. Differences between groups were tested 
using a generalized Hausman specification test.22  Age was categorized into three groups: 18-29, 30-
49 and 50-67.  Educational level measured socioeconomic position, three categories were used: 1) 
compulsory education (primary school, lower secondary school or less) 2) intermediate education 
(upper secondary school and post-secondary non-tertiary education), 3) tertiary education 
(undergraduate, graduate and postgraduate).   
Supplementary analyses 
Previous literature has shown that both length and repeated spells of unemployment are associated 
with deteriorations in health.23-25 To explore the effect of having several unemployment spells during 
the observation period, we compared individuals with multiple unemployment spells with those only 
experiencing one episode of unemployment.  
As health selection to unemployment has been found in previous studies,7-9, 11 an increase in 
the likelihood of purchasing psychotropic drugs around the time of unemployment could be 
attributed to such a selection process; individuals who develop depression may be more likely to lose 
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their job. It is also possible that people who become depressed or anxious identify their jobs as a 
source of distress and decide to resign at a period their mental health is deteriorating. To explore this 
we did supplementary analyses on purchases of drugs related to somatic conditions and pain, using 
the same working population and methods as the main analysis. We assessed outcomes defined by 
first-time purchases of medication for diabetes (ATC  A10A), obesity (A08A), thyroid disorders (H03A) 
and cardiovascular disease (C01, C02, C03, C07, C08, C09, C10, whichever occurred first ) as well as 
opioids (N02A), other analgesics/antipyretics (N02B), non-steroid anti- inflammatory medication and 
topical products for muscular pain (M01A and M02A). 
We considered it less likely that purchases of medication for somatic conditions and pain 
would be systematically related to an unemployment spell.  Based on previous literature we 
anticipated some associations between unemployment status and purchase of cardiovascular disease 
medications, 5, 26 but overall we expected lower estimates on somatic and pain related drugs 
compared to psychotropic drugs.  
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RESULTS 
Descriptive statistics at baseline (2004) are presented in table 1. Annual rates of unemployment in 
Norway over the study period ranged from 3.5% in 2005 steadily decreasing to 1.7% in 2008 and 
increasing to 2.9% in 2010.  Of the 271,971 (12%) individuals in the working population purchasing 
antidepressants for the first time during the observation period, 34,111 (13%) had at least one 
unemployment spell during the observation period. Similarly, of the 331,625 (14%) incident 
purchasers of hypnotics/sedatives, 32,570 (10%) had a period of unemployment. 251,221 individuals 
(11%) bought anxiolytic drugs in the observation period, 26,838 (11%) of these experienced 
unemployment. Antipsychotic medication was less commonly used; 95,287 (4%) individuals 
purchased antipsychotics for the first time between 2005 and 2010, 12,495 (13%) of these were 
unemployed at some point during the observation period. Of those purchasing antidepressants, 
hypnotics/sedatives and anxiolytics, 52%, 49% and 52%, respectively, were women, whilst relatively 
fewer (44%) of those purchasing antipsychotic medication were females. Individuals who 
experienced unemployment tended to be younger than those prescribed the various psychotropic 
drugs as a whole.
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Table 1  Descriptive statistics at baseline (2004) for all individuals who purchased psychotropic medication and for individuals both 
purchasing medication and being unemployed (study population) during the observation period (2005 to 2010). Gender 
distribution, age (mean and standard deviation (SD)) and proportion of individuals in each category. Median number of days 
of unemployment during the observation period in males (m)/females (f). No missing on gender and age.  
Baseline 
characteristics   
Anti-
depressants 
(N06A) 
Incident anti-
depressants 
purchase  
and 
unemployed 
Hypnotic/ 
sedative 
drugs 
(N05C) 
Incident 
hypnotics/ 
sedatives 
purchase and 
unemployed 
Anxiolytic 
drugs 
 (N05B )  
Incident 
anxiolytics 
purchase  
and 
unemployed 
Anti- 
psychotic 
drugs 
 (N05A) 
Incident 
antipsychotics 
purchase  
and 
unemployed 
N 271971 34111 331625 32570 251221 26838 95287 12495 
Women (%)  159979 (59) 16963 (52) 193502 (58) 16068 (49) 149828 (60) 14086 (52) 49993 (52) 5507 (44) 
Age (mean/SD)  41(11.8) 35 (10.8) 44 (12.0) 36 (11.6) 43  (12.0) 36 (11.3) 41(12.0) 34 (10.9) 
Age cat. (%)          
18-29 years 54816 (20) 12659 (37) 49845 (15) 10679 (33) 41548 (16) 9245 (35) 20094 (21) 5045 (40) 
30-49 years 145124 (53) 17605 (52) 159912 (48) 16597 (51) 125006 (50) 13737 (51) 49438 (52) 6081 (49) 
50-67 years 72031 (27) 3847 (11) 121686 (37) 5294 (16) 84667 (34) 3856 (14) 25755 (27) 1369 (11) 
Education (%)         
Compulsory  73815 (27) 13354 (39) 75846 (23) 12253 (38) 66774 (26) 10920 (41) 27284 (29) 5279 (42) 
10 
 
Intermediate 122005 (45) 13417 (39) 149279 (45) 13083 (40) 114902 (46) 10533 (39) 42296 (44) 4679 (38) 
Tertiary  66287 (24) 5049 (15) 97444 (29) 5312 (16) 62166 (25) 3748 (14) 21849 (23) 1623 (13) 
Missing (%) 9864 (4) 2291 (7) 9056 (3) 1922 (6) 7379 (3) 1637 (6) 3858 (4) 914 (7) 
Median no days 
unemployed; 
(male/female) 
 392 
(408/377) 
 389 
 (397/379) 
 392 
(406/384) 
 408 
(421/394) 
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In Figure 2 we present the within-person relative risk of incident psychotropic drug purchases 
in relation to timing of unemployment. There was an increasing trend in psychotropic drug purchase 
in all medication groups 1-3 months ahead of the first registered day of unemployment, with the 
peak one month before unemployment (more than double risk), and a decrease during the 
unemployment spell and in particular after the end of unemployment. Of the four psychotropic 
drugs, antidepressants had the highest estimated odds ratios (OR) in the month before 
unemployment (OR 2.68, 95% confidence interval (CI) 2.39 to 3.01), followed by hypnotics/sedatives 
(OR 2.21, 95% CI 1.97 to 2.48), anxiolytics (OR 2.18, 95% CI 1.91 to 2.48) and antipsychotics (OR 2.09, 
95% CI 1.76 to 2.48). As seen from the category “4 months or more” of the unemployment spell (4+), 
there was a tendency towards increased risk of first-time psychotropic drug purchase in longer 
unemployment spells. Overall risk estimates of psychotropic drug purchase during all periods of 
unemployment (month 1-4+, data not shown) was OR 1.68 (95% CI 1.61 to 1.76) in antidepressants, 
OR 1.47 (95% CI 1.40 to 1.54) in hypnotics/sedatives, OR 1.45 (95% CI 1.38 to 1.53) in anxiolytics and 
OR 1.44 (95% CI 1.34 to 1.54) in antipsychotics.  
(Figure 2 here) 
Subgroup analyses 
Analyses stratified by sex (Figure 3) gave slightly higher risk estimates in men, especially in the 
months before and during unemployment. The differences in antidepressant purchases between 
males and females were statistically significant (p < 0.05) at unemployment states -4, -3, -2, 1, 2 and 
4+. Corresponding results in hypnotics/sedatives concerned states -5, -4, -2, 1 and 4+; anxiolytics at 
states -2, -1, 1, 2, 4+ and +4; antipsychotics at states -5, -4, -1 and 4+.  
(Figure 3 here) 
Results of the age-stratified analyses (S-Figure 2) showed no large differences between age-
groups in the months before and during unemployment. However, compared to their younger peers, 
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the oldest employees (50-67 years) seemed to have elevated risk of first-time psychotropic drug 
purchase also in the months after ending an unemployment spell. The analyses stratified by 
educational level (S-Figure 3) also gave similar results as the main analysis.  
 
Supplementary analyses and robustness checks 
Of the employees included in the case-crossover samples, approximately 25% experienced more 
than one spell of unemployment, regardless of which psychotropic drug was studied. We performed 
separate analyses on employees with only one unemployment spell and those with two or more 
spells during the observation period. The result (S-Figure 4) showed that those experiencing only one 
unemployment spell, generally had higher odds ratios for purchasing psychotropic medication in the 
three months before and during unemployment, compared to those experiencing two or more spells.  
The supplementary analyses on drugs related to more somatic conditions and symptoms are 
presented in Figure 4. A list of medications included in each group, and descriptive statistics, are 
presented in the supplementary file (S-Table 1 and S-Table 2). As expected, the associations between 
unemployment and first-time purchase of these were lower than that of psychotropic drug purchase. 
However, first-time purchases of several of these drugs showed similar patterns as psychotropic 
drugs in the months before unemployment. We observed increased risk of first-time purchases in the 
months before unemployment for anti-diabetic drugs (association in the month before job loss (OR 
1.44, 95% CI 1.10 to 1.89)), cardiovascular drugs (OR 1.48, 95% CI 1.32 to 1.66), drugs for thyroid 
disorders OR 1.22, 95% CI 0.88 to 1.69), opioids (OR 1.77, 95% CI 1.66 to 1.89) and other 
analgesics/antipyretic drugs (OR 1.46, 95% CI 1.34 to 1.60). The risk of purchasing anti-obesity and 
anti-inflammatory drugs were quite similar (OR ≈ 1) comparing case and control periods.  
(Figure 4 here) 
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DISCUSSION 
Analysing the initiation of psychotropic drugs before, during and after unemployment in the entire 
Norwegian working population from 2005 to 2010, showed a two to threefold increase in the risk of 
first-time purchases of psychotropic drugs during the month before the date of unemployment, with 
an increasing trend in the three months ahead of unemployment. The rises were greater in males 
than females.  The estimated risk decreased steadily during the first three months of unemployment, 
but stayed on a higher level compared to the six months before unemployment. In the six months 
after the end of unemployment the risk estimates were close to those of six months before job loss. 
Supplementary analyses on several drugs prescribed for somatic and pain conditions showed some of 
the same trends as psychotropic drug purchase, but with a substantially lower level of risk increase.  
Strengths and limitations 
A major strength of the study is the linkage of several registries, providing individual level data on the 
entire Norwegian working population over a fairly long time span. The level of precision (exact dates) 
and objectivity in the ascertainment of outcomes (prescribed drugs) and exposure (unemployment) 
adds to a literature dominated by self-rated measures and aggregated data. The variety of drugs 
studied is also a new contribution to the literature. 
Another strength is that we could assess purchases of psychotropic medications with a case-
crossover design where individuals served as their own control. By design we then eliminated all 
time-invariant or slow-varying confounding. Such confounding factors include sex, past psychiatric 
illness, educational level, genetic vulnerability and other stable individual factors relevant for the use 
of psychotropic drugs. However, the case-crossover design still might be susceptible to time varying 
confounding and we cannot rule out the influence from such factors in our study. Further, trends in 
exposure may introduce bias in case-crossover studies,21 but we consider this less likely to concern 
our study as the risk of having a prescription of psychotropic drugs was equal (OR ≈ 1) between case 
and control periods six months before unemployment.  
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Purchases of prescribed psychotropic drugs were used as a proxy for mental health. 
Prescription of psychotropic medication is based on clinical evaluation by a doctor, but is only one of 
several potential treatments for mental illness. Those in our study population suffering from mental 
illness, but not on medication, or those receiving medications while hospitalized, could not be 
identified in the data.  Further, as we do not have available data on drug prescriptions before 2004 in 
Norway, “first-time purchases” refer to the observation period and not life-time purchases, some 
may have had prescriptions before 2004. This may imply that our estimates are lower than they 
would be if we did not have this exclusion criterion. Also, some people may have been unemployed, 
but for various reasons did not register as unemployed, hence not included in the study samples.  
Context and generalizability  
Mental health consequences of unemployment seems to be context-sensitive, and studies from 
different labour markets over time are needed to add pieces to the puzzle.4 A Swedish study using 
monthly data on unemployment and dispensed antidepressants found no evidence of an increase in 
the prevalence of antidepressant use following unemployment,27 while a recent study of the Swedish 
working population showed an increased risk of purchasing antidepressant drugs in workers exposed 
to workplace downsizing.28  Evidence from the USA on macro-level data showed that in the 
Northeast region of the country, antidepressant and anti-anxiety drug prescriptions increased by 10% 
when employment fell by 1%, while no such relationship was found in other parts of the country.29 A 
Dutch paper used 8 waves of the European Community Household Panel (N = 136,556) to investigate 
how self-perceived health was affected by labour force exit due to unemployment, retirement or 
economic inactivity. They found a yearly increase in the likelihood of poor self-rated health after 
unemployment (OR 1.06, 95% CI 1.03-1.09), applying to all educational groups and all European 
regions, except the Nordic countries.30 
Previous research indicates that a generous welfare state may buffer negative consequences 
of unemployment on mental health, measured by suicide rate and other health outcomes.4, 31  This 
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may affect the generalizability of our results outside of Norway and Scandinavia, as the social 
spending, level of social security and unemployment benefits and degree of unionization is high. 
Also, unemployment rates in Norway have been low (below 4%) compared to most countries in 
Europe during the entire observation period (including the financial crisis). Martikainen et al. (2006) 
confirmed previous findings indicating that excess mortality of the unemployed tend to be lower in 
regions of high unemployment, suggesting a higher degree of health selection effects when 
unemployment rates are low. This may concern our findings and their generalizability.32  
Interpretation and previous findings 
The case-crossover design does not rule out the possible influence of time varying ill health 
as a possible cause of job loss (i.e. selection to unemployment). Still, given the detailed information 
on time, and incident measures of both outcome and exposure, we interpret the steadily increasing 
trend with a peak one month ahead of unemployment, as stress related to the unemployment 
process having a causal effect on workers’ mental health. The high ORs 3-1 month before 
unemployment perfectly correlate in time with the general Norwegian notice period, corresponding 
with a plausible onset of job insecurity. Job insecurity has been found to affect the work environment 
and employees’ mental health negatively,18, 28 both in the short33 and long run, and downsizing are 
often lengthy processes not only limited to the notice period.34   
Being in a state of actual unemployment also implied higher risk of first-time psychotropic 
drug purchase compared to the risk 6 months before or 6 months after the end of unemployment. 
This corresponds to the previous literature on effects of unemployment on mental health referred to 
in the introduction. The findings that associations were stronger in males than females are in keeping 
with international studies of suicides during the Great Recession,2 and studies on unemployment and 
health from Eastern Europe and Spain,12 while several Swedish studies found no gender differences 
in the unemployment effect on mental health.12, 35, 36 A systematic review recently concluded that 
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results of subgroup analyses (gender, age, educational level, marital status etc.) in this field are 
mixed and context dependent.12   
When stratifying on one versus two or more unemployment spells, those experiencing their 
first and only spell had higher risk estimates than those experiencing multiple unemployment spells. 
A possible interpretation of this could be that the first time is the most stressful. Further, those with 
several spells might be employed in more unstable jobs and have lower expectations regarding stable 
employment, and that unemployment did not affect their mental health as badly as in those 
experiencing only one spell.  
 The literature on unemployment effects on physical health measures (except suicide) is 
scarce with mixed findings. There are few relevant studies on other outcomes than cardiovascular 
disease.5, 26 A Swedish study did not find any effects of job loss on severe cardiovascular diseases,37 
while a French study claimed that unemployment may impair cardiovascular health.38 Empirical 
evidence from Finland found only modest effects on mortality of unemployment due to 
downsizing.32In our study, incident purchases of drugs other than psychotropics increased in the 
months ahead of unemployment. A plausible explanation could be an increase in morbidity (e.g. pain 
and cardiovascular symptoms) as a response to stress and depression related to unemployment. 
Another explanation could be that mental distress in relation to job loss increases doctor visits per se. 
Doctor visits will in itself trigger medical examinations likely to detect other medical problems in 
need of treatment. This detection aspect could contribute to an increased observed morbidity 
amongst the unemployed, previously discussed in a systematic review concluding that unemployed 
people may be more likely than employed people to visit physicians, take medications or be admitted 
to general hospitals.39 The increasing drug purchases may support the health selection hypothesis of 
vulnerable employees being more prone to lose their job.7 Nevertheless, the rapidly increasing odds 
ratios close to the unemployment period points towards unemployment triggering ill health.  
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One could expect the relationship between personal finances (which may vary over time 
within individuals) and medication prices to affect the demand for drugs, especially when the 
household economy is under pressure during unemployment. However, the Norwegian 
reimbursement system to a large extent covers the expenses for psychotropic drugs and other drugs 
related to chronic conditions like diabetes, thyroid disease and cardiovascular disease. In countries 
with high prices on medication, personal finances and market forces could confound the association 
between drug purchase and unemployment, but we do not consider this to be a problem in our 
study.  
Interventions for the unemployed targeting mental health are sparsely studied. A systematic 
review from 2010 concluded that the evidence supporting the use of vocational interventions to 
improve reemployment and reduce mental distress was weak.40 However, evidence from the US41 
and Finland 42   indicate that psychological interventions targeting the unemployed effectively 
improved mental health and were positively associated with reemployment. A two to threefold risk 
increase in purchasing psychotropic drugs in the months before unemployment, compared to other 
periods of peoples’ lives, means that the potential for conducting preventive health care should be 
high during this period – especially in plants going through major downsizing or closure. These are 
often lengthy processes that imply job insecurity for both those being laid off and those surviving in a 
downsizing firm. An implication of our findings could be a strengthening of preventive health 
initiatives early in the unemployment process, for example through  joint working between 
employees, employers, occupational health services, organisers of public reemployment programs 
and general practitioners.  
CONCLUSION 
Although the detrimental effects of unemployment are widely recognized, the present study’s results 
underscore that mental health may deteriorate in the period prior to the actual date of job loss.  The 
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clinical implications of this might be a strengthening of preventive health initiatives early in the 
unemployment process. 
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What this paper adds 
• Numerous studies have reported an adverse effect of unemployment on mental health, 
but few studies have been able to analyse the whole unemployment process, especially 
how mental health is affected around the time of job-loss notification, before actual 
unemployment begins. 
• The level of precision (exact dates) and objectivity in the ascertainment of outcomes 
(prescribed and purchased drugs) and exposure (registered unemployment spells) adds 
to a literature dominated by self-reported health measures and aggregated 
unemployment data.  
• We found that the risk of having a first purchase of prescribed psychotropic drugs was 
highest one month before unemployment, indicating that preventive health initiatives 
should be strengthened around the time of notification, early in the unemployment 
process.  
• Sensitivity analyses on a range of drugs for somatic and pain conditions, not studied in 
the previous literature, showed similar trends as psychotropics, but with weaker 
associations. 
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Figures 
 
Figure 1  Flowchart of study population within each ATC-group. Those with at least one purchase of prescribed 
psychotropic drugs (outcome) and one or more unemployment spells lasting for >90 days (exposure) 
were included in the case-crossover samples (those within the oval lines). 
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 Figure 2  Odds ratios (OR) with 95% Confidence Intervals (CI) of having a first purchase of antidepressants, 
hypnotic/sedative drugs, anxiolytic drugs and antipsychotic drugs, respectively, while being in a state 
of unemployment (1-6 months before, 1,2,3,4 or more months during (between vertical lines) and 1-6 
months after the end of unemployment). Control periods = 12, 24 and 36 months before the date of 
drug purchase. Start of the observation period was January 1st 2005, ending on December 31st 2010.  
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 Figure 3  Odds ratios (OR) with 95% Confidence Intervals (CI) of having a first purchase of antidepressants, 
hypnotic/sedative drugs, anxiolytic drugs and antipsychotic drugs, respectively, while being in a state 
of unemployment (1-6 months before, 1,2,3,4 or more months during (between vertical lines)  and 1-6 
months after the end of unemployment). Control periods = 12, 24 and 36 months before the date of 
drug purchase. Start of the observation period was January 1st 2005, ending on December 31st 2010. 
Stratified by gender. 
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 Figure 4 Odds ratios (OR) with 95% Confidence Intervals (CI) of having a first purchase of anti-obesity drugs, 
anti-diabetic drugs, cardiovascular drugs, thyroid drugs, anti-inflammatory drugs, opioids and other 
analgesics and antipyretics while being in a state of unemployment (1-6 months before, 1,2,3,4 or 
more months during (between vertical lines) and 1-6 months after the end of unemployment). 
Control periods = 12, 24 and 36 months before the date of drug purchase. Start of the observation 
period was January 1st 2005, ending on December 31st 2010. 
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Supplementary File 
 
Study design 
In order to illustrate the case period (the 16 time states in relation to unemployment around the 
time of drug purchase) and the three control periods, we made a figure illustrating a case (S-Figure 
1). We estimated the risk (odds ratio) of being exposed to unemployment around the date of having 
a first purchase of a psychotropic drug (here: antidepressant). Dichotomous variables indicating each 
person’s time-state according to unemployment and psychotropic drug purchase were generated, 
making it possible to analyse the data with a conditional logistic fixed-effects estimator (within 
person), eliminating time-invariant confounding. In the analyses we compared the odds of exposure 
of unemployment within each individual’s case and control periods. 
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S-Figure 2  Case-crossover study design indicating the time of the event (drug purchase) and the exposure states 
of unemployment 1-6 months before the date of unemployment, the 1,2,3, 4 or more months during 
unemployment and 1-6 months after end of unemployment.   
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Medication list  
 
S-Table 1  Medications included in each outcome-group; N05A Antipsychotics, N05B Anxiolytics, N05C Hypnotics 
and sedatives, N06A Antidepressants. Daily defined doses (DDD) per 1000 inhabitants per day in the 
Norwegian population 2006-2010. See the report “Drug consumption in Norway 2006-2010” published 
by the Norwegian Institute of Public Health (2011:1) for details of consumption on each specific drug.  
ATC  ATC level name DDDs/1000 inhabitants/day 
    2005 2006 2007 2008 2009 2010 
N05A Antipsychotics   8.4 8.7 8.9 8.9 9.0 9.1 
N05B Anxiolytics   19.6 19.2 19.1 19.3 18.9 18.0 
N05C Hypnotics and sedatives 39.5 41.2 43.1 44.2 44.6 44.3 
N06A Antidepressants  48.4 49.0 51.0 51.7 51.6 52.8 
A08A Anti-obesity preparations, excl. diet products 2.6 2.3 2.7 3.0 3.1 0.9 
A10A  Insulins and analogues 17.1 17.5 17.8 18.5 18.5 18.7 
C01+C02+C03 
+C07+C08+C09 
+C10 
Cardiac therapy; Antihypertensives; Diuretics; Beta blocking agents; 
Calcium channel blockers; Agents acting on the renin-angiotensin 
system; Lipid modifying agents 46.6 49.2 51.8 54.7 55.7 57.0 
H03A Thyroid therapy     19.0 19.6 20.4 21.2 21.5 22.3 
M01A +M02A 
Antiinflammatory and antirheumatic products, nonsteroids; Topical 
products for joint and muscular pain 33.2 33.5 33.7 32.9 32.1 32.2 
N02A Opioids  17.1 17.3 17.4 18.0 18.1 17.7 
N02B Other analgesics and antipyretics 5.6 6.6 7.7 9.2 10.6 11.9 
         N05A  Antipsychotics 
 N05AA  Phenothiazines with aliphatic side chain 
 N05AA01  Chlorpromazine 
 N05AA02  Levomepromazine 
 N05AB  Phenothiazines with piperazine structure 
 N05AB01  Dixyrazine 
 N05AB02  Fluphenazine 
 N05AB03  Perphenazine 
 N05AB04  Prochlorperazine 
 N05AB06  Trifluoperazine 
 N05AB08  Thioproperazine 
 N05AC  Phenothiazines with piperidine structure 
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 N05AC01  Periciazine 
 N05AC02  Thioridazine 
 N05AC04  Pipotiazine 
 N05AD  Butyrophenone derivatives 
 N05AD01  Haloperidol 
 N05AD03  Melperone 
 N05AD08  Droperidol 
 N05AE03  Sertindole 
 N05AE04  Ziprasidone 
 N05AE05  Lurasidone 
 N05AF  Thioxanthene derivatives 
 N05AF01  Flupentixol 
 N05AF03  Chlorprothixene 
 N05AF05  Zuclopenthixol 
 N05AG  Diphenylbutylpiperidine derivatives 
 N05AG02  Pimozide 
 N05AG03  Penfluridol 
 N05AH  Diazepines, oxazepines, thiazepines and oxepines 
 N05AH01  Loxapine 
 N05AH02  Clozapine 
 N05AH03  Olanzapine 
 N05AH04  Quetiapine 
 N05AH05  Asenapine 
 N05AL  Benzamides 
 N05AL01  Sulpiride 
 N05AL03  Tiapride 
 N05AL05  Amisulpride 
 N05AN  Lithium 
 N05AN01  Lithium 
 N05AX  Other antipsychotics 
 N05AX07  Prothipendyl 
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 N05AX08  Risperidone 
 N05AX12  Aripiprazole 
 N05AX13  Paliperidone 
 N05B  Anxiolytics 
 N05BA  Benzodiazepine derivatives 
 N05BA01  Diazepam 
 N05BA02  Chlordiazepoxide 
 N05BA04  Oxazepam 
 N05BA05  Potassium clorazepate 
 N05BA06  Lorazepam 
 N05BA08  Bromazepam 
 N05BA09  Clobazam 
 N05BA12  Alprazolam 
 N05BB  Diphenylmethane derivatives 
 N05BB01  Hydroxyzine 
 N05BC  Carbamates 
 N05BC01  Meprobamate 
 N05BE  Azaspirodecanedione derivatives 
 N05BE01  Buspirone 
 N05C  Hypnotics and sedatives 
 N05CA  Barbiturates, plain 
 N05CA01  Pentobarbital 
 N05CA04  Barbital 
 N05CA06  Secobarbital 
 N05CB  Barbiturates, combinations 
 N05CB02  Barbiturates in combination with other drugs 
 N05CC  Aldehydes and derivatives 
 N05CC01  Chloral hydrate 
 N05CD  Benzodiazepine derivatives 
 N05CD01  Flurazepam 
 N05CD02  Nitrazepam 
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 N05CD03  Flunitrazepam 
 N05CD04  Estazolam 
 N05CD05  Triazolam 
 N05CD08  Midazolam 
 N05CF  Benzodiazepine related drugs 
 N05CF01  Zopiclone 
 N05CF02  Zolpidem 
 N05CF03  Zaleplon 
 N05CH  Melatonin receptor agonists 
 N05CH01  Melatonin 
 N05CM  Other hypnotics and sedatives 
 N05CM02  Clomethiazole 
 N05CM05  Scopolamine 
 N05CM06  Propiomazine 
 N05CM09  Valerianae radix 
 N05CM11  Bromides 
 N05CM18  Dexmedetomidine 
 N06  Psychoanaleptics 
 N06A  Antidepressants 
 N06AA  Non selective monoamine reuptake inhibitors 
 N06AA01  Desipramine 
 N06AA02  Imipramine 
 N06AA04  Clomipramine 
 N06AA05  Opipramol 
 N06AA06  Trimipramine 
 N06AA07  Lofepramine 
 N06AA08  Dibenzepin 
 N06AA09  Amitriptyline 
 N06AA10  Nortriptyline 
 N06AA11  Protriptyline 
 N06AA12  Doxepin 
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 N06AA21  Maprotiline 
 N06AB  Selective serotonin reuptake inhibitors 
 N06AB03  Fluoxetine 
 N06AB04  Citalopram 
 N06AB05  Paroxetine 
 N06AB06  Sertraline 
 N06AB08  Fluvoxamine 
 N06AB10  Escitalopram 
 N06AF  Monoamine oxidase inhibitors, non selective  
 N06AF01  Isocarboxazid 
 N06AF03  Phenelzine 
 N06AF04  Tranylcypromine 
 N06AG  Monoamine oxidase a inhibitors 
 N06AG02  Moclobemide 
 N06AX  Other antidepressants 
 N06AX01  Oxitriptan 
 N06AX02  Tryptophan 
 N06AX03  Mianserin 
 N06AX05  Trazodone 
 N06AX06  Nefazodone 
 N06AX09  Viloxazine 
 N06AX11  Mirtazapine 
 N06AX12  Bupropion 
 N06AX14  Tianeptine 
 N06AX16  Venlafaxine 
 N06AX18  Reboxetine 
 N06AX21  Duloxetine 
 N06AX22  Agomelatine 
 N06AX25  Hyperici herba 
 N06AX26  Vortioxetine 
 A08A  Antiobesity preparations, excl. diet products 
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 A08AA  Centrally acting antiobesity products 
 A08AA01  Phentermine 
 A08AA02  Fenfluramine 
 A08AA04  Dexfenfluramine 
 A08AA05  Mazindol 
 A08AA10  Sibutramine 
 A08AA56  Ephedrine, combinations 
 A08AB  Peripherally acting antiobesity products 
 A08AB01  Orlistat 
 A08AX  Other antiobesity drugs 
 A08AX01  Rimonabant 
 A10A  Insulins and analogues 
 A10AB  Insulins and analogues for injection, fast acting  
 A10AB01  Insulin (human) 
 A10AB03  Insulin (pork) 
 A10AB04  Insulin lispro 
 A10AB05  Insulin aspart 
 A10AB06  Insulin glulisine 
 A10AC  Insulins and analogues for injection, intermediate acting  
 A10AC01  Insulin (human) 
 A10AC03  Insulin (pork) 
 A10AC30  Combinations 
 A10AD  
Insulins and analogues for injection, intermediate or long combinded with fast 
acting  
 A10AD01  Insulin (human) 
 A10AD03  Insulin (pork) 
 A10AD04  Insulin lispro 
 A10AD05  Insulin aspart 
 A10AE  Insulins and analogues for injection, long acting  
 A10AE01  Insulin (human) 
 A10AE02  Insulin (beef) 
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 A10AE04  Insulin glargine 
 A10AE05  Insulin detemir 
 A10AE06  Insulin degludec 
 C01  Cardiac therapy 
 C01A  Cardiac glycosides 
 C01AA  Digitalis glycosides 
 C01AA04  Digitoxin 
 C01AA05  Digoxin 
 C01AB  Scilla glycosides 
 C01AB01  Proscillaridin 
 C01B  Antiarrhythmics, class i and iii 
 C01BA  Antiarrhythmics, class ia 
 C01BA01  Quinidine 
 C01BA02  Procainamide 
 C01BA03  Disopyramide 
 C01BA05  Ajmaline 
 C01BB  Antiarrhythmics, class ib 
 C01BB01  Lidocaine 
 C01BB02  Mexiletine 
 C01BC  Antiarrhythmics, class ic 
 C01BC03  Propafenone 
 C01BC04  Flecainide 
 C01BD  Antiarrhythmics, class iii 
 C01BD01  Amiodarone 
 C01BD02  Bretylium tosilate 
 C01BD05  Ibutilide 
 C01BD07  Dronedarone 
 C01BG  Other antiarrhythmics, class i and iii 
 C01BG11  Vernakalant 
 C01C  Cardiac stimulants excl. cardiac glycosides 
 C01CA  Adrenergic and dopaminergic agents 
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 C01CA01  Etilefrine 
 C01CA02  Isoprenaline 
 C01CA03  Norepinephrine 
 C01CA04  Dopamine 
 C01CA06  Phenylephrine 
 C01CA07  Dobutamine 
 C01CA09  Metaraminol 
 C01CA10  Methoxamine 
 C01CA13  Prenalterol 
 C01CA14  Dopexamine 
 C01CA17  Midodrine 
 C01CA24  Epinephrine 
 C01CA26  Ephedrine 
 C01CE  Phosphodiesterase inhibitors 
 C01CE01  Amrinone 
 C01CE02  Milrinone 
 C01CX  Other cardiac stimulants 
 C01CX08  Levosimendan 
 C01D  Vasodilators used in cardiac diseases 
 C01DA  Organic nitrates 
 C01DA02  Glyceryl trinitrate 
 C01DA08  Isosorbide dinitrate 
 C01DA14  Isosorbide mononitrate 
 C01DX  Other vasodilators used in cardiac diseases 
 C01DX12  Molsidomine 
 C01DX16  Nicorandil 
 C01E  Other cardiac preparations 
 C01EA  Prostaglandins 
 C01EA01  Alprostadil 
 C01EB  Other cardiac preparations 
 C01EB03  Indometacin 
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 C01EB09  Ubidecarenone 
 C01EB10  Adenosine 
 C01EB15  Trimetazidine 
 C01EB16  Ibuprofen 
 C01EB17  Ivabradine 
 C01EB18  Ranolazine 
 C01EB21  Regadenoson 
 C02  Antihypertensives 
 C02A  Antiadrenergic agents, centrally acting 
 C02AB  Methyldopa 
 C02AB01  Methyldopa (levorotatory) 
 C02AC  Imidazoline receptor agonists 
 C02AC01  Clonidine 
 C02AC05  Moxonidine 
 C02C  Antiadrenergic agents, peripherally acting 
 C02CA  Alpha adrenoreceptor antagonists 
 C02CA01  Prazosin 
 C02CA04  Doxazosin 
 C02CC  Guanidine derivatives 
 C02CC02  Guanethidine 
 C02D  Arteriolar smooth muscle, agents acting on 
 C02DB  Hydrazinophthalazine derivatives 
 C02DB01  Dihydralazine 
 C02DB02  Hydralazine 
 C02DC  Pyrimidine derivatives 
 C02DC01  Minoxidil 
 C02DD  Nitroferricyanide derivatives 
 C02DD01  Nitroprusside 
 C02K  Other antihypertensives 
 C02KD  Serotonin antagonists 
 C02KD01  Ketanserin 
39 
 
 C02KX  Antihypertensives for pulmonary arterial hypertension 
 C02KX01  Bosentan 
 C02KX02  Ambrisentan 
 C02KX03  Sitaxentan 
 C02KX04  Macitentan 
 C02KX05  Riociguat 
 C03  Diuretics 
 C03A  Low ceiling diuretics, thiazides  
 C03AA  Thiazides, plain 
 C03AA01  Bendroflumethiazide 
 C03AA03  Hydrochlorothiazide 
 C03AA06  Trichlormethiazide 
 C03AB  Thiazides and potassium in combination 
 C03AB01  Bendroflumethiazide and potassium 
 C03B  Low ceiling diuretics, excl. Thiazides 
 C03BA  Sulfonamides, plain 
 C03BA04  Chlortalidone 
 C03BA05  Mefruside 
 C03BA08  Metolazone 
 C03C  High ceiling diuretics  
 C03CA  Sulfonamides, plain 
 C03CA01  Furosemide 
 C03CA02  Bumetanide 
 C03CA04  Torasemide 
 C03CB  Sulfonamides and potassium in combination 
 C03CB02  Bumetanide and potassium 
 C03CC  Aryloxyacetic acid derivatives 
 C03CC01  Etacrynic acid 
 C03D  Potassium sparing agents 
 C03DA  Aldosterone antagonists 
 C03DA01  Spironolactone 
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 C03DA02  Potassium canrenoate 
 C03DA04  Eplerenone 
 C03DB  Other potassium sparing agents 
 C03DB01  Amiloride 
 C03DB02  Triamterene 
 C03E  Diuretics and potassium sparing agents in combination 
 C03EA  Low ceiling diuretics and potassium 
 C03EA01  Hydrochlorothiazide and potassium sparing agents 
 C03X  Other diuretics 
 C03XA  Vasopressin antagonists 
 C03XA01  Tolvaptan 
 C07  Beta blocking agents 
 C07A  Beta blocking agents 
 C07AA  Beta blocking agents, non selective 
 C07AA01  Alprenolol 
 C07AA02  Oxprenolol 
 C07AA03  Pindolol 
 C07AA05  Propranolol 
 C07AA06  Timolol 
 C07AA07  Sotalol 
 C07AA12  Nadolol 
 C07AB  Beta blocking agents, selective 
 C07AB02  Metoprolol 
 C07AB03  Atenolol 
 C07AB07  Bisoprolol 
 C07AB09  Esmolol 
 C07AB12  Nebivolol 
 C07AG  Alpha and beta blocking agents 
 C07AG01  Labetalol 
 C07AG02  Carvedilol 
 C07B  Beta blocking agents and thiazides 
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 C07BB  Beta blocking agents, selective, and thiazides 
 C07BB07  Bisoprolol and thiazides 
 C07BB12  Nebivolol and thiazides 
 C08  Calcium channel blockers 
 C08C  Selective calcium channel blockers with mainly vascular effects 
 C08CA  Dihydropyridine derivatives 
 C08CA01  Amlodipine 
 C08CA02  Felodipine 
 C08CA03  Isradipine 
 C08CA05  Nifedipine 
 C08CA06  Nimodipine 
 C08CA13  Lercanidipine 
 C08CX  Other selective calcium channel blockers with mainly vascular effects 
 C08CX01  Mibefradil 
 C08D  Selective calcium channel blockers with direct cardiac effects 
 C08DA  Phenylalkylamine derivatives 
 C08DA01  Verapamil 
 C08DB  Benzothiazepine derivatives 
 C08DB01  Diltiazem 
 C09  Agents acting on the renin angiotensin system 
 C09A  Ace inhibitors, plain 
 C09AA  Ace inhibitors, plain 
 C09AA01  Captopril 
 C09AA02  Enalapril 
 C09AA03  Lisinopril 
 C09AA04  Perindopril 
 C09AA05  Ramipril 
 C09AA09  Fosinopril 
 C09AA10  Trandolapril 
 C09AA15  Zofenopril 
 C09B  Ace inhibitors, combinations 
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 C09BA  Ace inhibitors and diuretics 
 C09BA02  Enalapril and diuretics 
 C09BA03  Lisinopril and diuretics 
 C09BA15  Zofenopril and diuretics 
 C09BB  Ace inhibitors and calcium channel blockers 
 C09BB02  Enalapril and lercanidipine 
 C09C  Angiotensin ii antagonists, plain 
 C09CA  Angiotensin ii antagonists, plain 
 C09CA01  Losartan 
 C09CA02  Eprosartan 
 C09CA03  Valsartan 
 C09CA04  Irbesartan 
 C09CA06  Candesartan 
 C09CA07  Telmisartan 
 C09CA08  Olmesartan medoxomil 
 C09D  Angiotensin ii antagonists, combinations 
 C09DA  Angiotensin ii antagonists and diuretics 
 C09DA01  Losartan and diuretics 
 C09DA02  Eprosartan and diuretics 
 C09DA03  Valsartan and diuretics 
 C09DA04  Irbesartan and diuretics 
 C09DA06  Candesartan and diuretics 
 C09DA07  Telmisartan and diuretics 
 C09DA08  Olmesartan medoxomil and diuretics 
 C09DB  Angiotensin ii antagonists and calcium channel blockers 
 C09DB01  Valsartan and amlodipine 
 C09DB02  Olmesartan medoxomil and amlodipine 
 C09DX  Angiotensin ii antagonists, other combinations 
 C09DX01  Valsartan, amlodipine and hydrochlorothiazide 
 C09DX03  Olmesartan medoxomil, amlodipine and hydrochlorothiazide 
 C09X  Other agents acting on the renin angiotensin system 
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 C09XA  Renin inhibitors 
 C09XA02  Aliskiren 
 C09XA52  Aliskiren and hydrochlorothiazide 
 C10  Lipid modifying agents 
 C10A  Lipid modifying agents, plain 
 C10AA  Hmg coa reductase inhibitors 
 C10AA01  Simvastatin 
 C10AA02  Lovastatin 
 C10AA03  Pravastatin 
 C10AA04  Fluvastatin 
 C10AA05  Atorvastatin 
 C10AA06  Cerivastatin 
 C10AA07  Rosuvastatin 
 C10AA08  Pitavastatin 
 C10AB  Fibrates 
 C10AB01  Clofibrate 
 C10AB02  Bezafibrate 
 C10AB04  Gemfibrozil 
 C10AB05  Fenofibrate 
 C10AC  Bile acid sequestrants 
 C10AC01  Colestyramine 
 C10AC02  Colestipol 
 C10AC04  Colesevelam 
 C10AD  Nicotinic acid and derivatives 
 C10AD01  Niceritrol 
 C10AD02  Nicotinic acid 
 C10AD06  Acipimox 
 C10AD52  Nicotinic acid, combinations 
 C10AX  Other lipid modifying agents 
 C10AX02  Probucol 
 C10AX06  Omega 3 triglycerides incl. other esters and acids 
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 C10AX09  Ezetimibe 
 C10B  Lipid modifying agents, combinations 
 C10BA  Hmg coa reductase inhibitors in combination with other lipid modifying agents 
 C10BA02  Simvastatin and ezetimibe 
 C10BA05  Atorvastatin and ezetimibe 
 H03A  Thyroid preparations 
 H03AA  Thyroid hormones 
 H03AA01  Levothyroxine sodium 
 H03AA02  Liothyronine sodium 
 H03AA03  Combinations of levothyroxine and liothyronine 
 H03AA04  Tiratricol 
 H03AA05  Thyroid gland preparations 
 M01A  Antiinflammatory and antirheumatic products, non steroids  
 M01AA  Butylpyrazolidines 
 M01AA01  Phenylbutazone 
 M01AB  Acetic acid derivatives and related substances 
 M01AB01  Indometacin 
 M01AB02  Sulindac 
 M01AB05  Diclofenac 
 M01AB15  Ketorolac 
 M01AB16  Aceclofenac 
 M01AB55  Diclofenac, combinations 
 M01AC  Oxicams 
 M01AC01  Piroxicam 
 M01AC06  Meloxicam 
 M01AE  Propionic acid derivatives 
 M01AE01  Ibuprofen 
 M01AE02  Naproxen 
 M01AE03  Ketoprofen 
 M01AE14  Dexibuprofen 
 M01AE17  Dexketoprofen 
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 M01AE52  Naproxen and esomeprazole 
 M01AG  Fenamates 
 M01AG02  Tolfenamic acid 
 M01AH  Coxibs 
 M01AH01  Celecoxib 
 M01AH02  Rofecoxib 
 M01AH03  Valdecoxib 
 M01AH04  Parecoxib 
 M01AH05  Etoricoxib 
 M01AH06  Lumiracoxib 
 M01AX  Other antiinflammatory and antirheumatic agents, non steroids  
 M01AX01  Nabumetone 
 M01AX05  Glucosamine 
 M02A  Topical products for joint and muscular pain 
 M02AA  Antiinflammatory preparations, non steroids for topical use 
 M02AA07  Piroxicam 
 M02AA10  Ketoprofen 
 M02AA13  Ibuprofen 
 M02AA15  Diclofenac 
 M02AB  Capsaicin and similar agents 
 M02AB01  Capsaicin 
 M02AC  Preparations with salicylic acid derivatives 
 M02AX  Other topical products for joint and muscular pain 
 M02AX10  Various 
 N02A  Opioids 
 N02AA  Natural opium alkaloids 
 N02AA01  Morphine 
 N02AA03  Hydromorphone 
 N02AA05  Oxycodone 
 N02AA08  Dihydrocodeine 
 N02AA51  Morphine, combinations 
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 N02AA55  Oxycodone, combinations 
 N02AA59  Codeine, combinations excl. psycholeptics 
 N02AB  Phenylpiperidine derivatives 
 N02AB01  Ketobemidone 
 N02AB02  Pethidine 
 N02AB03  Fentanyl 
 N02AB72  Pethidine, combinations with psycholeptics 
 N02AC  Diphenylpropylamine derivatives 
 N02AC01  Dextromoramide 
 N02AC03  Piritramide 
 N02AC04  Dextropropoxyphene 
 N02AC54  Dextropropoxyphene, combinations excl. psycholeptics 
 N02AD  Benzomorphan derivatives 
 N02AD01  Pentazocine 
 N02AE  Oripavine derivatives 
 N02AE01  Buprenorphine 
 N02AG  Opioids in combination with antispasmodics 
 N02AG01  Morphine and antispasmodics 
 N02AG02  Ketobemidone and antispasmodics 
 N02AG03  Pethidine and antispasmodics 
 N02AX  Other opioids 
 N02AX02  Tramadol 
 N02AX06  Tapentadol 
 N02AX52  Tramadol, combinations 
 N02B  Other analgesics and antipyretics 
 N02BA  Salicylic acid and derivatives 
 N02BA01  Acetylsalicylic acid 
 N02BA11  Diflunisal 
 N02BA51  Acetylsalicylic acid, combinations excl. psycholeptics 
 N02BB  Pyrazolones 
 N02BB01  Phenazone 
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 N02BB02  Metamizole sodium 
 N02BB51  Phenazone, combinations excl. psycholeptics 
 N02BB54  Propyphenazone, combinations excl. psycholeptics 
 N02BE  Anilides 
 N02BE01  Paracetamol 
 N02BE05  Propacetamol 
 N02BE51  Paracetamol, combinations excl. psycholeptics 
 N02BE71  Paracetamol, combinations with psycholeptics 
 N02BG  Other analgesics and antipyretics 
 N02BG07  Flupirtine 
 N02BG08  Ziconotide 
 N02BG10  Cannabinoids 
 
 
 
 
48 
 
 Descriptive statistics of the “supplementary” study population (other drugs than psychotropics) 
 
S-Table 2  Descriptive statistics at baseline (2004) for individuals on medication and individuals both on medication and unemployed (study population) during the observation 
period (2005-2010). Gender distribution, age (mean and standard deviation (SD)) and proportion of individuals in each category. No missing on gender and age.  
Baseline 
characteristics   
Anti-
obesity 
drugs 
(A08) 
A08 + 
unempl. 
Anti- 
diabetic 
drugs  
(A10A )  
A10A + 
unempl. 
Heart  
therapy  
(C01+ C02+ 
C03+ C07+ 
C08+C09+ 
C10) 
C01-C10 
 + unempl. 
Thyroid  
therapy  
(H03A) 
H03A + 
unempl. 
Anti- 
inflammatory  
and  
anti-rheumatic 
drugs 
(M01A+M02A) 
M01A+M02A 
+ unempl. 
N 69 636  7577 (11) 82446  7085 (9) 582862  37015 (6) 101090 7 148 (7) 1509625 130032 (9) 
Women (%)  52 376 (75) 5 795 (76) 32090 (39) 2910 (41) 261209 (45) 15735 (43) 81524 (81) 5685 (80) 739845 (49) 59449 (46) 
Age (mean/SD)  39(11.2) 34 (10.1) 46  (11.8) 40 (12.0) 48 (10.5) 43 (11.6) 45(11.6) 38 (11.6) 40 (12.1) 35 (11.3) 
Age cat. (%)            
18-29 years 14842 (21) 3045 (40) 9301 (11) 1575 (22) 34750 (6) 5344 (14) 11982 (12) 1822 (25) 326446 (21) 50046 (39) 
30-49 years 40013 (58) 3895 (52) 35005 (43) 3606 (51) 244080 (42) 18720 (51) 18808 (48) 3845 (54) 780856 (52) 62912 (48) 
50-67 years 14781 (21) 637 (8) 38140 (46) 1904 (27) 304032 (52) 12951 (35) 40300 (40) 1481 (21) 402323 (27) 17074 (13) 
Education (%)           
Compulsory  17712 (25) 2849 (38) 19269 (23) 2406 (34) 121467 (21) 11686 (31) 18956 (19) 2050 (29) 335896 (22) 47386 (36) 
Intermediate 34436 (50) 3334 (44) 40882 (50) 3121 (44) 291762 (50) 17653 (48) 46561 (46) 3052 (43) 715790 (47) 54016 (42) 
Tertiary  15005 (22) 956 (12) 19657 (24) 1037 (15) 158531 (27) 5902 (16) 33196 (33) 1604 (22) 415297 (28) 20081 (15) 
Missing (%) 2033 (3) 438 (6) 2638 (3) 521 (7) 11102 (2) 1774 (5) 2377 (2) 442 (6) 42642 (3) 8549 (7) 
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S-Table 2 (cont.)  Descriptive statistics at baseline (2004) for individuals on medication and individuals both on medication and unemployed (study population) during the observation 
period (2005-2010). Gender distribution, age (mean and standard deviation (SD)) and proportion of individuals in each category. No missing on gender and age.  
Baseline 
characteristics   
Opioids  
(N02A) 
N02A + 
unempl. 
Analgesics/ 
antipyretics 
(N02B )  
N02B + 
unempl. 
N 939357 87301 (9) 469107 42518 (9) 
Women (%)  454445 (48) 39358(45) 251132 (54) 21125 (50) 
Age (mean/SD)  41(12.2) 35 (11.3) 42  (12.0) 36 (11.4) 
Age cat. (%)      
18-29 years 199247 (21) 33616 (39) 78886 (17) 14372 (34) 
30-49 years 477729 (51) 42352 (48) 239428 (51) 21753 (51) 
50-67 years 262381 (28) 11333 (13) 150793 (32) 6393 (15) 
Education (%)     
Compulsory  222486 (24) 33404 (39) 114966 (25) 16398 (38) 
Intermediate 444198 (47) 35747 (41) 227336 (48) 17740 (42) 
Tertiary  245383 (26) 12501 (14) 112703 (24) 5350 (13) 
Missing (%) 27290 (3) 5649 (6) 14102 (3) 3030 (7) 
 
50 
 
Psychotropic drug purchase stratified by age and educational level 
In order to reduce the number of figures in the paper, we present the stratified analyses of the main 
analysis in S-Figure 2 and S-Figure 3 below. The results are commented in the paper.  
 
S-Figure 2 Odds ratios (OR) with 95% Confidence Intervals (CI) of having a first purchase of antidepressants, 
hypnotic/sedative drugs, anxiolytic drugs and antipsychotic drugs, respectively, while being in a state 
of unemployment (1-6 months before, 1,2,3,4 or more months during (between vertical lines)  and 1-6 
months after the end of unemployment). Control periods = 12, 24 and 36 months before the date of 
drug purchase. Start of the observation period was January 1st 2005; the end was December 31st 2010. 
Stratified by age. 
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S-Figure 3  Odds ratios (OR) with 95% Confidence Intervals (CI) of having a first purchase of antidepressants, 
hypnotic/sedative drugs, anxiolytic drugs and antipsychotic drugs, respectively, while being in a state 
of unemployment(1-6 months before, 1,2,3,4 or more months during (between vertical lines)  and 1-6 
months after the end of unemployment). Control periods = 12, 24 and 36 months before the date of 
drug purchase. Start of the observation period was January 1st 2005; the end was December 31st 2010. 
Stratified by educational level. 
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Unemployment frequency during the observation period (2005 to 2010)  
 
As having repeated unemployment spells can be associated with deteriorated health (see main 
manuscript), we wanted to explore the effect of potentially having several unemployment spells 
during the observation period. We compared individuals with multiple unemployment spells with 
those only experiencing one episode of unemployment. The results are commented in the paper:  
 
S-Figure 4 Odds ratios (OR) with 95% Confidence Intervals (CI) of having a first purchase of antidepressants, 
hypnotic/sedative drugs, anxiolytic drugs and antipsychotic drugs, respectively, while being in a state 
of unemployment (1-6 months before, 1,2,3,4 or more months during (between vertical lines)  and 1-6 
months after the end of unemployment). Control periods are 12, 24 and 36 months before the date of 
drug purchase. Start of the observation period was January 1st 2005; the end was December 31st 
2010. Stratified by 1 vs. 2 or more unemployment spells during the observation period. 
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STROBE statement 
The authors confirm that the STROBE checklist was followed in this article: 
 Item 
No Recommendation 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the 
abstract 
Author: Study design(case-crossover)  is included in the title 
(b) Provide in the abstract an informative and balanced summary of what 
was done and what was found 
Author: See abstract.  
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the investigation being 
reported 
Author: See sections one and two in the introduction.  
Objectives 3 State specific objectives, including any prespecified hypotheses 
Author: See sections three, four and five in the introduction.  
Methods 
Study design 4 Present key elements of study design early in the paper 
Author: See sections under the subheadings “Data provision” and “Design 
and study population”. Also, see the illustration of the study design in S-
table 1 in the supplementary file.  
Setting 5 Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection 
Author: See sections under the subheadings “Data provision” and “Design 
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and study population” 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and methods 
of selection of participants. Describe methods of follow-up 
Case-control study—Give the eligibility criteria, and the sources and 
methods of case ascertainment and control selection. Give the rationale for 
the choice of cases and controls 
Cross-sectional study—Give the eligibility criteria, and the sources and 
methods of selection of participants 
Author: Case-crossover study: See sections under the subheadings “Data 
provision” and “Design and study population”. Also, see figure 1.  
(b) Cohort study—For matched studies, give matching criteria and number 
of exposed and unexposed 
Case-control study—For matched studies, give matching criteria and the 
number of controls per case 
Author: In the case-crossover design, individuals are matched with 
themselves – at different times in life. See sections under the subheading 
“Design and study population” 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, 
and effect modifiers. Give diagnostic criteria, if applicable 
Author: See sections under subheadings “Outcome ascertainment” and 
“Exposure to unemployment”. Confounding is commented in the first 
section under the subheading “Design and study population”.  
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods of 
assessment (measurement). Describe comparability of assessment methods 
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if there is more than one group 
Author: All data was provided from national registries. See sections under 
subheading “Data provision”.  
Bias 9 Describe any efforts to address potential sources of bias 
Author: See first sections under subheadings “Design and study 
population” and “Main analysis”. 
Study size 10 Explain how the study size was arrived at 
Author: See sections under subheadings “Data provision”, Design and 
study population”. Also, see figure 1.  
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If 
applicable, describe which groupings were chosen and why 
Author: See sections under subheadings “Data provision”, “Main analysis” 
and “Subgroup analyses”  
Statistical methods 12 (a) Describe all statistical methods, including those used to control for 
confounding 
Author: See sections under subheadings “Main analysis” and “Subgroup 
analyses” 
(b) Describe any methods used to examine subgroups and interactions 
Author: See section under subheading “Subgroup analyses”. Also, see 
comments on stratified analyses in the supplementary file.  
(c) Explain how missing data were addressed 
Author: There were no missing data in the main analyses, as commented 
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in table 1.  
(d) Cohort study—If applicable, explain how loss to follow-up was addressed 
Case-control study—If applicable, explain how matching of cases and 
controls was addressed 
Cross-sectional study—If applicable, describe analytical methods taking 
account of sampling strategy 
Author: Case-crossover. Right censoring (loss to follow-up) was described 
under the subheading “Outcome ascertainment”.   
(e) Describe any sensitivity analyses 
Author: Sensitivity/supplementary analyses are described under the 
subheading “Supplementary analyses”.  
Results 
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers 
potentially eligible, examined for eligibility, confirmed eligible, included in 
the study, completing follow-up, and analysed 
Author: See Figure 1 and Table 1.  
(b) Give reasons for non-participation at each stage 
Author: See “Design and study population” under Methods.  
(c) Consider use of a flow diagram 
Author: See Figure 1.  
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) 
and information on exposures and potential confounders 
Author: See Table 1 in the manuscript and S-Table 1 and S-Table 2 in the 
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supplementary file. Also, see the first section under “Results”.  
(b) Indicate number of participants with missing data for each variable of 
interest 
Author: See Table 1 in the manuscript and S-Table 2 in the supplementary file. 
(c) Cohort study—Summarise follow-up time (eg, average and total amount) 
Author: Not relevant in a case-crossover. The observation period was 2005 to 
2010, as described in the second section under the subheading ”Design and 
study population”.   
Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time 
Case-control study—Report numbers in each exposure category, or summary 
measures of exposure 
Author: Case-crossover study – all study participants are both exposed and have 
the outcome, as described in “Methods” under the subheading “Design and study 
population” and in Figure 1.  
Cross-sectional study—Report numbers of outcome events or summary measures 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted 
estimates and their precision (eg, 95% confidence interval). Make clear 
which confounders were adjusted for and why they were included 
Author: See the second section under “Results”. Also, see Figure 2-4 providing 
odds rations with 95% confidence intervals.  
(b) Report category boundaries when continuous variables were categorized 
Author: See Table 1.  
(c) If relevant, consider translating estimates of relative risk into absolute risk 
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for a meaningful time period 
Author: Not relevant. 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and 
sensitivity analyses 
Author: See Figure 3-4 in the manuscript and S-Figure 2-4 in the supplementary file.  
Discussion 
Key results 18 Summarise key results with reference to study objectives 
Author: See section one under “Discussion”.  
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or 
imprecision. Discuss both direction and magnitude of any potential bias 
Author: See subheading “Strengths and limitations”.  
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, 
multiplicity of analyses, results from similar studies, and other relevant evidence 
Author: See subheadings “Strengths and limitations”, “Previous studies” and 
“Interpretation”.  
Generalisability 21 Discuss the generalisability (external validity) of the study results 
Author: See section under subheading “Context and generalizability”  
Other information 
Funding 22 Give the source of funding and the role of the funders for the present study and, if 
applicable, for the original study on which the present article is based 
Author: See section under subheading “Funding”. 
 
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and 
unexposed groups in cohort and cross-sectional studies. 
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